ApoB — the cholesterol number cardiologists increasingly trust over LDL

Q: What's the difference between ApoB and "non-HDL cholesterol"?

Non-HDL cholesterol (total cholesterol − HDL) approximates the cholesterol carried by all atherogenic lipoproteins. It's a reasonable proxy when ApoB isn't available, but it still measures mass, not particle count. ApoB is more precise where the discordance matters (insulin resistance, small dense LDL phenotype).

Q: If my LDL is normal but my ApoB is elevated, what's the explanation?

Usually small dense LDL phenotype — common in insulin resistance, often paired with high triglycerides and low HDL. The right intervention typically addresses both the cholesterol picture and the underlying metabolic dysfunction.

Paired condition: High cholesterol lab work

Quick answer

ApoB (apolipoprotein B) counts the number of atherogenic particles in your blood. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB on its surface — so measuring ApoB tells you how many "bad" cholesterol particles are circulating, regardless of how much cholesterol each one is carrying. For cardiovascular risk, particle *count* often matters more than particle *mass* (which is what LDL-C measures). Many cardiologists and lipidologists now prefer ApoB as the primary risk marker.

Reference ranges and interpretation

Value / population	Classification	What it means
< 80 mg/dL	Optimal	Typical target for high cardiovascular risk patients.
< 90	Low risk	General population target.
90 – 109	Borderline	Moderate risk depending on other factors.
110 – 129	High	Significant cardiovascular risk in most adults.
≥ 130	Very high	Aggressive intervention is usually appropriate.

Lipidology guidelines increasingly target ApoB < 80 for primary prevention in high-risk patients and < 65 for secondary prevention (already had a cardiovascular event). The specific target depends on risk profile.

What different values typically indicate

ApoB < 80 mg/dL: consistent with low cardiovascular risk from a lipoprotein standpoint. Worth confirming the rest of the panel (HDL, triglycerides, Lp(a), inflammation) matches.

ApoB 80 – 100: moderate. Risk math depends heavily on other factors (age, family history, blood pressure, smoking, diabetes status, Lp(a), inflammation). The same ApoB can be low-risk or high-risk depending on context.

ApoB > 100: elevated atherogenic particle count. Significant cardiovascular risk in most adults. Lifestyle and (often) pharmacologic intervention warranted.

ApoB > 130: high. Aggressive intervention is usually appropriate, particularly in patients with additional risk factors. Statins are typically first-line; ezetimibe and PCSK9 inhibitors add when statin alone is insufficient.

Why ApoB beats LDL-C in many contexts

The classic LDL-C number measures the total cholesterol mass carried inside LDL particles. The problem: LDL particles vary in size. Patients with insulin resistance often have many small, dense LDL particles that carry less cholesterol per particle — so LDL-C looks normal-ish while the actual particle count (and atherogenic risk) is elevated.

ApoB cuts through that by counting particles directly. Two patients with the same LDL-C of 110 can have ApoB 85 (lower particle count, healthier overall) vs ApoB 125 (high particle count, much higher actual risk). LDL-C can't distinguish these; ApoB does.

This is why "discordant" lipid panels — LDL-C low but ApoB high — are common in metabolic syndrome, and why many cardiologists have shifted to ApoB-first risk assessment.

What to look at alongside ApoB

ApoB is a strong single marker, but the picture includes:

- LDL-C — traditional anchor; often discordant with ApoB in metabolic disease
- HDL — protective lipoprotein
- Triglycerides — metabolic marker that often pairs with high ApoB
- Lp(a) — genetic; measure once in every adult
- hs-CRP — inflammation
- Glucose / fasting insulin — metabolic context
- Blood pressure — major risk modifier
- Family history — genetic risk modifier
- Coronary artery calcium (CAC) — direct visualization of existing plaque

For comprehensive risk assessment, ApoB + Lp(a) + hs-CRP + CAC is the modern lipidology stack — far more informative than LDL-C alone.

Phi Longevity reads every marker on every lab you upload — together, against your history, against optimal ranges, and across time. The integrated picture tells you what a single number can't.

Start with my labs →

Frequently asked questions

Why doesn't every doctor order ApoB?

Inertia. Decades of guidelines centered on LDL-C, residency training emphasized LDL-C, and insurance coverage for ApoB has historically been less reliable. The lipidology field has moved; primary care is catching up. You can typically request ApoB explicitly.

Is ApoB a fasting test?

ApoB is less affected by fasting than triglycerides or directly-measured LDL. Many labs report ApoB on both fasting and non-fasting samples reliably. For consistent longitudinal comparison, fasting is preferred.

Can lifestyle change move ApoB?

Yes, but with limits. Dietary patterns lower in saturated fat and refined carbohydrates, weight loss, exercise, and reduced alcohol can lower ApoB 10–25% in most patients. Patients with strongly genetic hypercholesterolemia or familial elevated Lp(a) often need medication regardless.

Is the ApoB target the same for everyone?

No. General population target is typically < 90. Diabetics and patients with established cardiovascular disease should target < 80 or < 65 respectively. Elevated Lp(a) may shift the ApoB target lower. Your specific target should be set with your provider based on overall risk profile.

What's the difference between ApoB and "non-HDL cholesterol"?

Non-HDL cholesterol (total cholesterol − HDL) approximates the cholesterol carried by all atherogenic lipoproteins. It's a reasonable proxy when ApoB isn't available, but it still measures mass, not particle count. ApoB is more precise where the discordance matters (insulin resistance, small dense LDL phenotype).

If my LDL is normal but my ApoB is elevated, what's the explanation?

Usually small dense LDL phenotype — common in insulin resistance, often paired with high triglycerides and low HDL. The right intervention typically addresses both the cholesterol picture and the underlying metabolic dysfunction.

References

All citations verified against PubMed / publisher of record 2026-05-26.

1.Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 73(24):e285-e350. — Current US standard for the role of ApoB in cardiovascular risk assessment; basis for the diagnostic-threshold framing on this page.PubMed →DOI →
2.Kronenberg F, Mora S, Stroes ESG, et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 43(39):3925-3946. — Reference for Lp(a) particles as a subset of ApoB-containing particles; basis for the "Lp(a) + ApoB + hs-CRP + CAC stack" framing.PubMed →DOI →
3.Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina MJ, Catapano AL, Ference BA. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 4(12):1287-1295. — The definitive narrative review establishing why ApoB outperforms LDL-C. Basis for the "discordant LDL-C / ApoB phenotype" + "small dense LDL in insulin resistance" framing.PubMed →DOI →
4.Cannon CP, Blazing MA, Giugliano RP, et al. (IMPROVE-IT Investigators). (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 372(25):2387-2397. — IMPROVE-IT supports lower-the-better LDL/ApoB targets in high-risk patients.PubMed →DOI →

Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab. All citations verified vs PubMed / publisher of record 2026-05-26.

By Steve Pinedo

Co-founder, Phi Longevity

Last updated: 2026-05-26

Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi Longevity →

High cholesterol lab work

The full lipid pattern this particle count lives in.

Triglycerides

Metabolic marker that often pairs with high ApoB.

Metabolic syndrome

The pattern that drives discordant LDL / ApoB.